Back to Search
Start Over
Review of the recent advances of pyrazole derivatives as selective COX-2 inhibitors for treating inflammation.
- Source :
-
Molecular diversity [Mol Divers] 2024 Jul 16. Date of Electronic Publication: 2024 Jul 16. - Publication Year :
- 2024
- Publisher :
- Ahead of Print
-
Abstract
- Pyrazole heterocycle is regarded as an extremely significant agent for the therapy of inflammation. Celecoxib, lonazolac, deracoxib, and phenylbutazone are examples of commercially approved pyrazole drugs with COX-2 inhibitory potential for curing inflammation. There have been recently many reviews for the biological significance of pyrazole derivatives. This review talks about pyrazole derivatives with anti-inflammatory activity and also sheds the light on the recent updates on pyrazole research with an emphasis on some synthetic pathways utilized to construct this privileged scaffold and structure activity relationship that accounts for the anti-inflammatory activity in an attempt to pave the opportunity for medicinal chemists to develop novel anti-inflammatory agents with better COX-2 selectivity.<br /> (© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)
Details
- Language :
- English
- ISSN :
- 1573-501X
- Database :
- MEDLINE
- Journal :
- Molecular diversity
- Publication Type :
- Academic Journal
- Accession number :
- 39014146
- Full Text :
- https://doi.org/10.1007/s11030-024-10906-9